GlassScriptPhysician profile
Gary A Bonacquisti
NPI 1881652311
$2,037.28
in general payments reported to CMS, 2019-2025
24 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $147 · 2021: $52.11 · 2022: $252 · 2023: $621 · 2024: $36.21 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.95 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $275.75 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $256.35 | 2019-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $180.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $161.47 | 2019-2023 | Breztri, Farxiga |
| Pfizer INC. | $128.16 | 2019-2023 | |
| Amgen INC. | $103.26 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $100.47 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $56.68 | 2022-2023 | Mounjaro |
| Boston Scientific Corporation | $49.45 | 2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Janssen Pharmaceuticals, INC | $48.62 | 2020-2023 | Spravato |
| Renalytix Ai, INC. | $38.85 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $36.82 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $34.15 | 2019 | |
| Dexcom, INC. | $20.79 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.13 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2022 | |
| Aytu Biopharma, INC. | $15.93 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.82 | 2020 | |
| Amarin Pharma, INC. | $14.93 | 2019 | |
| Melinta Therapeutics, LLC | $14.87 | 2019 | |
| Esperion Therapeutics, INC. | $14.17 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.46 | 2019 | |
| Ironshore Pharmaceuticals INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bonacquisti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.